We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab.
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) / De Angelis, C; Bruzzese, D; Bernardo, A; Baldini, E; Leo, L; Fabi, A; Gamucci, T; De Placido, P; Poggio, F; Russo, S; Forestieri, V; Lauria, R; De Santo, I; Michelotti, A; Del Mastro, L; De Laurentiis, M; Giuliano, M; De Placido, S; Arpino, G. - In: ESMO OPEN. - ISSN 2059-7029. - 6:2(2021), p. 100054. [10.1016/j.esmoop.2021.100054]
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
De Angelis, CPrimo
;Bruzzese, D;Bernardo, A;Baldini, E;De Placido, P;Forestieri, V;Lauria, R;De Santo, I;Michelotti, A;De Laurentiis, M;Giuliano, M;De Placido, SPenultimo
;Arpino, GUltimo
2021
Abstract
We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab.| File | Dimensione | Formato | |
|---|---|---|---|
|
main.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
329.15 kB
Formato
Adobe PDF
|
329.15 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
